Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Fabry Disease Therapeutics Pipeline Report 2016 - Review of 12 Companies & 14 Molecules - Research and Markets

Research and Markets
Posted on: 30 Sep 16

Research and Markets has announced the addition of the "Fabry Disease - Pipeline Review, H2 2016" report to their offering.

Fabry Disease pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. Our latest report Fabry Disease - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Fabry Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Fabry Disease Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called globotriaosylceramide) in blood vessel walls throughout the body. Symptoms include pain, diarrhea, nausea, kidney problems, tinnitus, irregular heartbeat, and leaky heart valves. Treatment includes enzyme replacement therapy (ERT). The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 2, 2 and 6 respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Fabry Disease and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Fabry Disease Overview
  3. Therapeutics Development
  4. Pipeline Products for Fabry Disease - Overview
  5. Pipeline Products for Fabry Disease - Comparative Analysis
  6. Fabry Disease - Therapeutics under Development by Companies
  7. Fabry Disease - Therapeutics under Investigation by Universities/Institutes
  8. Fabry Disease Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Fabry Disease - Products under Development by Companies
  13. Fabry Disease - Products under Investigation by Universities/Institutes
  14. Fabry Disease - Companies Involved in Therapeutics Development
  • Actelion Ltd
  • Alexion Pharmaceuticals Inc
  • Amicus Therapeutics, Inc.
  • Genzyme Corporation
  • Greenovation Biotech GmbH
  • ISU ABXIS Co.,Ltd.
  • JCR Pharmaceuticals Co., Ltd.
  • Neuraltus Pharmaceuticals, Inc.
  • Pharming Group N.V.
  • Protalix BioTherapeutics, Inc.
  • Sangamo BioSciences, Inc.
  • Shire Plc

For more information about this report visit

View source version on

Business Wire

Last updated on: 30/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.